US biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Tuesday the publication of an original research article titled 'Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis' in the New England Journal of Medicine (NEJM) Evidence.
The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalised Pustular Psoriasis (GPP), submitted to the US Food and Drug Administration (FDA) with a target action date of 12 December 2026.
Imsidolimab is a fully humanised IgG4 monoclonal antibody that inhibits IL-36 receptor signalling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s.
Vanda holds an exclusive global licence for the development and commercialisation of imsidolimab from AnaptysBio (Nasdaq:ANAB).
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
Pharming secures FDA acceptance of Joenja filing for children with APDS
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan